In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upfront Payments in Biotech Deals

Executive Summary

How much are biotech companies receiving upfront on average from their collaborators, relative to the clinical phase of the product being licensed? To find out, we took 445 deals since 1989 in which an upfront payment was made and broke out the average upfront license fees and equity payments by clinical phase of the most advanced product licensed in the deal.
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel